Nautica Enterprises NAUT 深 沪
等待开盘 08-13 09:30:00 美东时间
0.7129
-0.007
-1.03%
华盛通- 最 高0.7336
- 今 开0.712
- 成交量 12.94万股
- 最 低 0.71
- 昨 收 0.7203
- 总市值 8982.54万
- 52周最高 3.09
- 市盈率 静 --
- 换手率 0.10%
- 52周最低 0.66
- 委 比 29.94%
- 总股本 1.26亿
- 历史最高 12.38
- 量 比 0.41
- 振 幅 3.28%
- 历史最低 0.66
- 每 手 1
- 风险率 0.25%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Nautilus Biotechnology’s Q2 2025 Financial Highlights
Nautilus Biotechnolgy, Inc. ( ($NAUT) ) has released its Q2 earnings. Here is a...
08-01 13:25
Earnings Scheduled For July 31, 2025
Companies Reporting Before The Bell • Vanguard Extended Duration Treasury ETF (...
07-31 16:32
Nautilus Biotechnology Enters Into An Agreement With The Allen Institute Focused On Investigating The Connection Between The Tau Protein And Neurodegenerative Conditions Such As Alzheimer's Disease
Allen Institute to employ Iterative Mapping, Nautilus' single-molecule proteomics method, to investigate connection between tau protein and Alzheimer's disease• Agreement links the organizations' next-generation
07-30 20:09
Nautilus Biotechnology Announces Agreement with the Allen Institute, Further Validating its Approach to Single-Molecule Proteomics
<p>Nautilus Biotechnology and the Allen Institute have teamed up to investigate the connection between the tau protein and Alzheimer’s disease using Nautilus’ Iterative Mapping method. Their goal is to identify novel tau proteoforms, quantify their prevalence, and understand phosphorylation patterns that could predict disease progression. This collaboration leverages single-molecule proteomics to advance diagnostics and treatments for neurodegene...
07-30 12:00
Nautilus Biotechnology to Announce Second Quarter 2025 Financial Results on July 31, 2025
Nautilus Biotechnology, Inc. will report second quarter 2025 financial results on July 31, 2025, before market open. A webcast conference call to discuss results and business developments will begin at 5:30 a.m. PT / 8:30 a.m. ET, available on www.nautilus.bio.
07-15 12:00
Nautilus Biotechnology Announces Board Restructuring
An update from Nautilus Biotechnolgy ( ($NAUT) ) is now available. Nautilus Bio...
06-24 05:01
NeuroPace Announces Promising NAUTILUS Study Results
NeuroPace ( ($NPCE) ) just unveiled an announcement. On May 27, 2025, NeuroPace...
05-27 20:29
NeuroPace Announces Preliminary Primary Endpoint 1-Yr Results Of Two-Year NAUTILUS Study Evaluating Safety And Effectiveness Of RNS System For Treatment Of Individuals With Drug-Resistant IGE
-- NeuroPace has completed the primary endpoint analysis of the one-year data from the first and only clinical study to evaluate neuromodulation therapy for idiopathic generalized epilepsy-- Study met the 12-week
05-27 20:12
Nautilus Biotechnology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
Nautilus Biotechnology, Inc. will participate in the Goldman Sachs 46th Annual Global Healthcare Conference. Its management will join a fireside chat on June 10, 2025, at 2:00 p.m. ET. The presentation will be available live and archived on the company’s website. Nautilus is a life sciences company focused on developing a platform to quantify the proteome, aiming to advance proteomics and human health. For more information, visit www.nautilus.bio...
05-27 12:00
Nauticus Robotics Reports Strong Start to 2025
Revenue Momentum Builds; Strategic Acquisition Positions Company for Accelerated Growth HOUSTON, May 14, 2025 /PRNewswire/ -- Nauticus Robotics, Inc. ("Nauticus" or the "Company") (NASDAQ: K...
05-15 07:39
